Press "Enter" to skip to content

Hemispherx Biopharma initiated with a Buy rating and $8 price target at Maxim – Proactive Investors USA & Canada

admin 0

Hemispherx Biopharma initiated with a Buy rating and $ 8 price target at Maxim  Proactive Investors USA & Canada

Hemispherx Biopharma Inc (NYSE:HEB) – Analyst Jason McCarthy says that with a $ 10M valuation and potentially positive data expected over 2019 and 2020, …

“colorectal cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *